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Available online 2 November 2021The COVID-19 pandemic has brought health inequalities into
sharp focus on an international scale. Vulnerability to and mortality
from acute COVID-19 infection is higher in men [1], whereas, Long
COVID disproportionately affects women [2]. Why?
A recent review [3] on Long COVID highlights the multi-organ
sequalae following infection, articulating a pressing need for greater
understanding of the mechanisms in the post-acute phase, to guide
research for effective management. Underlying mechanisms include
virus-associated pathologies, immunological dysfunction and inflam-
matory-mediated damage [3]. However, despite the stark asymmetry
in risk and outcomes between sexes, sex-specific pathophysiology
receives little attention in this review [3].
Sex-specific risk and ultimately outcomes are multifactorial - a
function of the complex interplay between biology, behaviour, and
the wider determinants of health. Wenham et al. [4] describe impor-
tant factors which result in disproportionate risk to women’s socio-
economic positions and health during the COVID-19 pandemic. These
factors set the stage for the disproportionate impact that Long COVID
has on women. Female sex and age under 50 years are now acknowl-
edged as risk factors for Long COVID [2]. However, recognised predic-
tors of acute COVID mortality risk [1] (increasing age, chronic
comorbidity, male sex) fail to predict poor outcomes in Long COVID.2
In fact, Long COVID risk appears to be largely unaffected by pre-exist-
ing comorbidities or disability [2], making identification of at-risk
women more difficult  a problem for both women and clinicians.
Despite the already vulnerable socioeconomic positions of women
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is likely far more challenging for perimenopausal and menopausal
women who already experience significant and additional inequality
in the workplace [5].
From a biological perspective, we propose the asymmetry in risk
and outcomes between sexes, and an overlap of symptoms of Long
COVID [3] with those of perimenopause and menopause [6] point
towards sex hormone differences as targets for further investigation.
Furthermore, the higher prevalence of Long COVID in women under
the age of 50 years [2] is an important and supporting clue as the
mean age of natural menopause (in the UK) is 51 years [6].
Oestrogen and androgen receptors are ubiquitous, present in
almost all tissues in the body, evidencing the widespread and impor-
tant roles of sex hormones [7], well beyond their obvious roles in the
reproductive system. Viral-induced sex hormone dysfunction result-
ing in early menopause, menstruation abnormalities and miscarriage
are documented in HIV and Hepatitis B and C infections [8]. In the
context of viral infections, sex hormone dysfunction may be related
to multisystem disruption or due to organ-specific effects [8]. The
role of sex hormones in COVID-19 infection are now beginning to
emerge. A recent study [9] highlights important clinical and immuno-
logical differences between sexes in acute COVID-19 infection;
women had lower mortality, lower levels of inflammation, higher
lymphocyte counts, and faster antibody responses than men. Specifi-
cally, oestradiol may be implicated here [7] owing to its immuno-
modulatory effects [7] as well as antiplatelet and vasodilatory
activity [7]. Observational research [8] highlights transient menstrua-
tion abnormalities during acute COVID-19 possibly owing to the
expression of the ACE2 receptor proteins in the ovaries [8]. Such find-
ings support a hypothesis of temporary disruption to physiological
ovarian steroid hormone production, which could acutely exacerbate
symptoms of perimenopause and menopause.
Many symptoms of Long COVID [3] (fatigue, muscle aches, palpita-
tions, cognitive impairment, sleep disturbance) have a significant
overlap with the perimenopause and menopause [6], both which can
affect women of all ages. Such overlap may create diagnostic uncer-
tainty and requires clinicians to assess for this additional diagnosis aser the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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symptoms with safe and effective hormone replacement therapy
(HRT) [6]. Failure to recognise this overlap misses an opportunity to
treat many debilitating symptoms affecting both physical and mental
health, but also to reduce some women’s risk of cardiovascular dis-
ease, type 2 diabetes, osteoporosis, obesity and possibly dementia [6]
- all of which increase after the menopause. Furthermore, it could
lead to womenwith symptoms of the perimenopause andmenopause
being misdiagnosed with Long COVID.
Identification of patients at highest risk of Long COVID is now of
great importance [2,3]. This allows prioritisation of resources for
those in greatest clinical need, along with identifying multi-speciality
teams [2]. Clinicians working in Long COVID clinics should receive
training in menopause care so perimenopausal and menopausal
women can be promptly diagnosed and offered appropriate manage-
ment. Screening for and diagnosis of perimenopause and menopause
is simple and quick, does not usually involve serum sex hormone
analysis [6], and should be routinely performed in all women in Long
COVID clinics. Changes in menstruation are often early signs of peri-
menopause [6]; other common symptoms of perimenopause and
menopause include hot flushes, memory problems, brain fog,
reduced stamina, fatigue, anxiety, low mood, joint pains and head-
aches [6]. Clinicians should actively enquire about all of these symp-
toms. Where appropriate, a trial of HRT is a safe and useful treatment
option [6] for women and clinicians to consider, as an improvement
in symptoms supports a diagnosis of hormone deficiency.
Failure to explore sex-specific risk and outcomes in COVID-19 is
unethical [10] and associated with several risks. Firstly, it threatens
opportunities for identifying mechanisms and treatment targets,
where at present, no treatments exist. Secondly, it threatens global
women’s health at present and in the future, owing to the risk of mis-
diagnosing Long Covid instead of the perimenopause and meno-
pause, and failing to implement appropriate treatment strategies.
Thirdly, it threatens global economic recovery and future prepared-
ness due to the highly gendered nature of work and female domi-
nated sectors such as health and social care [4]
Looking ahead, there is urgent need for robust research to help
understand the epidemiological basis, as well as the underlying bio-
logical mechanisms for sex-differences in Long COVID. The deficit in
sex and gender-specific outcomes within clinical trials is recognised,
with calls for the systematic application of sex-specific methodolo-
gies [10]. Sex-disaggregated data underpins this vital research, along
with power calculations which consider sex as an analytical variable
a priori [10].Contributors
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